Human 4-1BBR/TNFRSF9 (Recombinant)

Product Description

Human 4-1BBR/TNFRSF9
Catalog number: B2010338
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 10 ug
pH: 7.4 upon reconstitution
Supplied as: Lyophilized Powder
Appearance: Powder
Applications: highly pure Human 4-1BBR/TNFRSF9 expressed in E. coli. This protein acts as an inducible T cell molecule belonging to the TNF receptor superfamily, involved in the expansion of antigen-specific T cells as well as in the inhibition of activation-induced death of CD8+ T cells.
Storage: -20C
Keywords: rHu4-1BBR/TNFRSF9; CD137
Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: So T, Ishii N. The TNF-TNFR Family of Co-signal Molecules. Adv Exp Med Biol.
2019;1189:53-84.

2: Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang B, Liu Z, Jin L, Xing
R, Gao R, Zhang L, Dong M, Hu X, Ren X, Kirchhoff D, Roider HG, Yan T, Zhang Z.
Global characterization of T cells in non-small-cell lung cancer by single-cell
sequencing. Nat Med. 2018 Jul;24(7):978-985.

3: Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang P, Xu A, Liao-Chan S, Sen D, Nager
AR, Oakdale NS, Brown C, Wang F, Yang Y, Lindquist K, Yeung YA, Salek-Ardakani
S, Chaparro-Riggers J. Structure of the 4-1BB/4-1BBL complex and distinct
binding and functional properties of utomilumab and urelumab. Nat Commun. 2018
Nov 8;9(1):4679.

4: Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP,
Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas
RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by
tonic signaling of chimeric antigen receptors. Nat Med. 2015 Jun;21(6):581-90.

5: Chu DT, Bac ND, Nguyen KH, Tien NLB, Thanh VV, Nga VT, Ngoc VTN, Anh Dao DT,
Hoan LN, Hung NP, Trung Thu NT, Pham VH, Vu LN, Pham TAV, Thimiri Govinda Raj
DB. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int J Mol
Sci. 2019 Apr 12;20(8):1822.

6: Etxeberria I, Glez-Vaz J, Teijeira Á, Melero I. New emerging targets in
cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open. 2020
Jul;4(Suppl 3):e000733.

7: Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K,
Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone
CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G. Antitumor
Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via
Chimeric Antigen Receptor T Cells. Cancer Cell. 2019 Feb 11;35(2):221-237.e8.

8: Kumar P, Bhattacharya P, Prabhakar BS. A comprehensive review on the role of
co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
J Autoimmun. 2018 Dec;95:77-99.
9: Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X. Optimization of 4-1BB
antibody for cancer immunotherapy by balancing agonistic strength with FcγR
affinity. Nat Commun. 2019 May 20;10(1):2141.

Products Related to Human 4-1BBR/TNFRSF9 : Proteins